Alembic Pharmaceuticals Limited · NSE:APLLTD

Alembic Pharmaceuticals — Investor Presentation (June 2019)

13 slides from Alembic Pharmaceuticals's investor presentation, June 2019

  1. Slide 1: Alembic Pharmaceuticals Limited Investor presentation – June 2019

    Alembic Pharmaceuticals Limited Investor presentation – June 2019 BSE & NSE: APLLTD

  2. Slide 2: Milestones

    Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed 2012 Formed a JV, Rhizen, for NCE research Launched fir

  3. Slide 3: Financial Highlights

    Financial Highlights INR Bn Particulars Q1 FY20 Q1 FY19 Growth FY19 Net Sales 9.49 8.63 10% 39.35 EBIDTA Pre R&D 3.64 2.65 37% 13.38 Margin % 38% 31% 34% R&D 1.40 1.21 16% 4.98 R&D % 15% 14% 13% EBIDTA Post R&D 2.33 1.51 54% 8.75 Margin % 25% 18% 22% Net Profit 1.24 0.90 37% 5.84 Capex 1.74 1.56 6.2

  4. Slide 4: Business snapshot

    Business snapshot Formulations Generics Branded API Total US Ex-US India Revenue Q1FY20 (INR Bn) 3.45 1.08 3.24 1.72 9.49 API Vet 18% 18% 4% Generics Q1FY20 Revenue 36% 48% Contribution Acute 9% Branded 11% 34% Speciality 21% Growth Q1FY20 -14% -2% -4% 53% 10% over Q1FY19 • Well-established US front

  5. Slide 5: US Generic

    US Generic Revenue – Q1 FY20 INR Bn Revenue – Last 5 Years CAGR - 42% INR Bn 12.28 12.88 3.45 9.19 9.20 2.26 3.16 Q1FY19 Q1FY20 FY15 FY16 FY17 FY18 FY19 Approved ANDAs Milestones & Updates Derma 3 Opthalmic 8  The Oncology OSD facility at panelav was successfully audited by USFDA with Zero 483s Tot

  6. Slide 6: Ex-US Generics

    Ex-US Generics Revenue : Q1 FY20 INR Bn Revenue – Last 5 Years INR Bn CAGR - 17% 1.26 1.08 4.94 Q1FY19 Q1FY20 3.20  Presence in following markets 2.86 2.66 - Europe, Canada, Australia, Brazil and South Africa 2.34  The business will focus on new launches across key markets  Plant successfully aud

  7. Slide 7: API

    API Revenue : Q1 FY20 INR Bn Revenue – Last 5 Years INR Bn CAGR - 20% 1.80 1.72 7.71 6.40 6.51 Q1FY19 Q1FY20 5.25  Sales across geographies as preferred supplier 3.67  Investing in plants to create additional capacities  FDA Compliant plants  State of the art R&D center and Process development l

  8. Slide 8: R&D Significant investments in building capabilities

    R&D Significant 8.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 37* Filing 6.0 13.7% 13.1% 12.7% 29 Approval 10.1% R&D Spend 4.0 20 19 18* * 11 Filings & 6.3% 7 Approvals 5.0 R&D % of were 2.0 4.3 4.1 10 sales 8 contributed by 3.2 7 7 5 acquisition of 1.3 Orit,

  9. Slide 9: State of the art facilities and infrastructure

    State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Oct’18* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables H1FY21# F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic H2FY2

  10. Slide 10: Branded Business

    Branded Business Revenue – Q1 FY20 INR Bn Revenue – Last 5 Years CAGR - 6% INR Bn 13.8 12.5 12.7 3.31 3.23 11.8 11.0 0.36 0.38 Vet 0.92 0.89 Acute Speciality 2.03 1.96 Q1FY19 Q1FY20 FY15 FY16 FY17 FY18 FY19 Marketing Organization Key Achievements  5000 + Marketing team  5 Brands in top 300  17 Ma

  11. Slide 11: Therapy-wise Performance Q1 FY20

    Therapy-wise Performance Q1 FY20 QTR JUN 19 QTR JUN 18 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 11 2.10 8 1% 11 2.17 14 37% Anti Diabeti

  12. Slide 12: Financials: Generating consistent returns

    Financials : Generating consistent returns Revenue EBIDTA Capex INR Bn INR Bn INR Bn 10.07 39.35 6.04 6.26 8.75 31.62 31.34 31.31 4.91 6.15 6.42 20.53 3.09 4.03 2.13 FY15 FY16 FY17 FY18 FY19 FY15 FY16 FY17 FY18 FY19 FY15 FY16 FY17 FY18 FY19 CAGR - 18% CAGR - 21% Net Profit EBIDTA margin % ROCE % INR

  13. Slide 13: Thank you

    Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu

Alembic Pharmaceuticals — Investor Presentation (June 2019) on 6ix